CellSystems to Distribute Minerva Biotechnologies' NaA-ve Stem Cell Culture System in Europe.
M2 PHARMA-March 2, 2018-CellSystems to Distribute Minerva Biotechnologies' NaA-ve Stem Cell Culture System in Europe
(C)2018 M2 COMMUNICATIONS
- Waltham, Massachusetts-based cancer immunotherapy and regenerative medicine company Minerva Biotechnologies has signed a European distribution agreement with Troisdorf, Germany-based life science supplier CellSystems GmbH for the AlphaSTEM Naive Stem Cell Culture System, the company said.
AlphaSTEM Culture System is a simple, natural method for inducing the naive state in human stem cells without the use of biochemical inhibitors.
Naive stem cells do not yet have DNA methylation marks that have already committed the cells to certain developmental decisions.
Directed differentiation efficiency and functionality are increased with 'clean slate' AlphaSTEM naive cells. Stem cells cultured in AlphaSTEM maintain normal karyotype for at least 70 passages.
Stem cell expansion is faster and scalable, and can be completely automated since it eliminates unwanted spontaneous differentiation.
Further, iPSC generation in AlphaSTEM Culture System is orders of magnitude more efficient than FGF-based reprogramming.
Minerva Biotechnologies generates human naive state induced pluripotent stem cells (iPS cells) using a single, naturally occurring human stem cell growth factor that is only expressed in the naive cells of the inner cell mass during the earliest days of embryogenesis.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 2, 2018|
|Previous Article:||Improved Sepsis Monitoring Protocol Reduces Mortality Rate by 85%.|
|Next Article:||BMG Pharma Partners with Pierre Fabre to Launch Pain, Healing Products for Oral Lesions.|